BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing

Reuters11-18

BRIEF-Dermata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> terminates license agreement with Villani dated March 31, 2017, says in SEC Filing

Nov 18 (Reuters) - Dermata Therapeutics Inc DRMA.O:

DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILING
DERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILING
DERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE

Further company coverage: DRMA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584501939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584501939","market":"nz","top_or_hot":-1,"title":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> terminates license agreement with Villani dated March 31, 2017, says in SEC Filing</title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a> <span>DRMA.O</span>:</p><ul><li><p>DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILING</p></li><li><p>DERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILING</p></li><li><p>DERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE</p></li></ul><p>Further company coverage: <span>DRMA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> terminates license agreement with Villani dated March 31, 2017, says in SEC Filing</title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a> <span>DRMA.O</span>:</p><ul><li><p>DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILING</p></li><li><p>DERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILING</p></li><li><p>DERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATE</p></li></ul><p>Further company coverage: <span>DRMA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRMA","symbol_name":"Dermata Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0G4:1","article_id":"2584501939","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584501939","pubTimestamp":1763464096,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC FilingNov 18  - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATEFurther company coverage: DRMA.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRMA":"Dermata Therapeutics Inc","BK4007":"制药","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"简介-Dermata Therapeutics在SEC文件中表示，终止与Villani于2017年3月31日签订的许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9},"content_text":"BRIEF-Dermata Therapeutics terminates license agreement with Villani dated March 31, 2017, says in SEC FilingNov 18 (Reuters) - Dermata Therapeutics Inc DRMA.O:DERMATA THERAPEUTICS INC - ON NOV 17, TERMINATES LICENSE AGREEMENT WITH VILLANI DATED MARCH 31, 2017 - SEC FILINGDERMATA THERAPEUTICS INC - TERMINATION LINKED TO STRATEGIC SHIFT TO OTC SKIN CARE - SEC FILINGDERMATA THERAPEUTICS : VILLANI WILL NOT BE ENTITLED TO RECEIVE ANY FURTHER MILESTONES OR OTHER PAYMENTS DUE AFTER TERMINATION DATEFurther company coverage: DRMA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584501939","isCrawlerRequest":true}